Phase II study of enlonstobart (SG001), a novel PD-1 inhibitor in patients with PD-L1 positive recurrent/metastatic cervical cancer. Li G, Li X, Yin R, Feng M, et al. Gynecol Oncol 2024;191:165-171.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Li G, Li X, Yin R, Feng M, et al. Phase II study of enlonstobart (SG001), a novel PD-1 inhibitor in patients with PD-L1 positive recurrent/metastatic cervical cancer. Gynecol Oncol 2024;191:165-171.
PMID: 39447517